Skip to main content
    • Aa
    • Aa

Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies

  • Alfred Asante-Korang (a1) (a2), Jeffrey P. Jacobs (a3) (a2), Jeremy Ringewald (a1), Jennifer Carapellucci (a1), Kristin Rosenberg (a1), Daniel McKenna (a1), Jorge McCormack (a1) (a2), Ivan Wilmot (a1), Abigail Gjeldum (a1), Mayra Lopez-Cepero (a4) and John Sleasman (a5) (a2)...

Highly sensitised children in need of cardiac transplantation have overall poor outcomes because of increased risk for dysfunction of the cardiac allograft, acute cellular and antibody-mediated rejection, and vasculopathy of the cardiac allograft. Cardiopulmonary bypass and the frequent use of blood products in the operating room and cardiac intensive care unit, as well as the frequent use of homografts, have predisposed potential recipients of transplants to allosensitisation. The expansion in the use of ventricular assist devices and extracorporeal membrane oxygenation has also contributed to increasing rates of allosensitisation in candidates for cardiac transplantation. Antibodies to Human Leukocyte Antigen can be detected before transplantation using several different techniques, the most common being the “complement-dependent lymphocytotoxicity assays”. “Solid-phase assays”, particularly the “Luminex® single antigen bead method”, offer improved specificity and more detailed information regarding specificities of antibodies, leading to improved matching of donors with recipients. Allosensitisation prolongs the time on the waiting list for potential recipients of transplantation and increases the risk of complications and death after transplantation. Aggressive reduction of antibodies to Human Leukocyte Antigen in these high-risk patients is therefore of vital importance for long-term survival of the patient and cardiac allograft. Strategies to decrease Panel Reactive Antibody or percent reactive antibody before transplantation include plasmapheresis, intravenous administration of immunoglobulin, and specific treatment to reduce B-cells, particularly Rituximab. These strategies have resulted in varying degrees of success. Antibody-mediated rejection and cardiac allograft vasculopathy are two of the most important complications of transplantation in patients with high Panel Reactive Antibody. The treatment of antibody-mediated rejection in recipients of cardiac transplants is largely empirical and includes the use of high-dose corticosteroids, plasmapheresis, intravenous administration of immunoglobulins, anti-thymocyte globulin, and Rituximab. Cardiac allograft vasculopathy is believed to be secondary to chronic complement-mediated endothelial injury and chronic vascular rejection. The use of proliferation signal inhibitors, such as sirolimus and everolimus, has been shown to delay the progression of cardiac allograft vasculopathy. In some non-sensitised recipients of cardiac transplants, the de novo formation of antibodies to Human Leukocyte Antigen after transplantation may increase the likelihood of adverse clinical outcomes. The use of serial testing for donor-specific antibodies after cardiac transplantation may be advisable in patients with frequent episodes of rejection and patients with history of sensitisation. Allosensitisation before transplantation can negatively influence outcomes after transplantation. A high incidence of antibody-mediated rejection and graft vasculopathy can result in graft failure and decreased survival. Current strategies to decrease allosensitisation have helped to expand the pool of donors, improve times on the waiting list, and decrease mortality. Centres of transplantation offering desensitisation are currently using plasmapheresis to remove circulating antibodies; intravenous immunoglobulin to inactivate antibodies; cyclophosphamide to suppress B-cell proliferation; and Rituximab to deplete B-lymphocytes. Similar approaches are also used to treat antibody-mediated rejection after transplantation with promising results.

Corresponding author
Correspondence to: Alfred Asante-Korang, MB CHB, MRCP, Clinical Associate Professor of Pediatrics, University of South Florida College of Medicine, Pediatric Cardiology Associates, 601 5th Street South, Suite 711, Saint Petersburg, Florida, 33701, United States of America. Tel: 727-322-4852; Fax: 727-821-2461; E-mail:
Hide All
1.Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report – 2007. J Heart Lung Transplant 2007; 26: 769781.
2.Velez M, Johnson MR. Management of allosensitized cardiac transplant candidates. Transplant Rev (Orlando) 2009; 23: 235247.
3.Itescu S, Schuster M, Burke E, et al. Immunologic consequences of assist devices. Cardiol Clin 2003; 21: 119133.
4.Eckman PM. Immunosuppression in the sentisized heart transplant recipient. Curr Opin Organ Transplant 2010; 15: 650656.
5.Jacobs JP, Quintessenza JA, Boucek RJ, et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 2004; 78: 17031709.
6.Kobashigawa JA, Sabad A, Drinkwater D, et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996; 94 (9 Suppl): II294II297.
7.Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgarter WA, Conte JV. Influence of pre-transplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 2007; 84: 15561562; discussion 62-63.
8.Ballew CC, Bergin JD. Management of patients with preformed reactive antibodies who are awaiting cardiac transplantation. Am J Crit Care 2005; 14: 4651.
9.Schuster M, Kocher A, John R, et al. B-cell activation and allosensitization after left ventricular assist device implantation is due to T-cell activation and CD40 ligand expression. Hum Immunol 2002; 63: 211220.
10.Drakos SG, Stringham JC, Long JW, et al. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. J Thorac Cardiovasc Surg 2007; 133: 16121619.
11.Joyce DL, Southard RE, Torre-Amione G, Noon GP, Land GA, Loebe M. Impact of left ventricular assist device-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant 2005; 24: 20542059.
12.Baran DA, Gass AL, Galin ID, et al. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device. J Heart Lung Transplant 2005; 24: 18861890.
13.Nikaein A, Cherikh W, Nelson K, et al. Organ procurement and transplantation network/united network of organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation 2009; 87: 557562.
14.Rhee JK, McGee E, Subacius H, et al. The impact of virtual crossmatch on cardiac allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2010; 29: S153.
15.Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999; 18: 701706.
16.Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant 2006; 20: 476484.
17.John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-Human Leukocyte Antigen alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100: II229II235.
18.Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of Cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002; 105: 12141219.
19.Balfour IC, Fiore A, Graff RJ, Knutsen AP. Use of Rituximab to decrease panel-reactive antibodies. J Heart Lung Transplant 2005; 24: 628630.
20.Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of Rituximab in organ transplantation. Transpl Int 2006; 19: 621628.
21.Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo depletion with Rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13: 5562.
22.Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity immunosuppression: one year outcomes. Am J Transplant 2010; 10: 382388.
23.Lick SD, Vaidya S, Kollar AC, et al. Peri-operative alemtuzumab (campath-1H) and plasmapheresis for high Panel Reactive Antibody positive lymphocyte crossmatch heart transplant: a strategy to shorten LVAD support. J Heart Lung Transplant 2008; 27: 10361039.
24.Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 15551561.
25.Patel J, Kittelson M, Reed E, et al. The effectiveness of a standardized desensitization protocol in reducing calculated panel reactive antibodies in sensitized heart transplant candidates: does it make sense to desensitize? J Heart Lung Transplant 2010; 29: S103.
26.Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007; 26: 876882.
27.Wright EJ, Fiser WP, Edens RE, et al. Cardiac transplant outcomes in pediatric patients with pre-formed anti-HLA antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant 2007; 26: 11631169.
28.Pollock-BarZiv SM, den Hollander N, Ngan BY, et al. Pediatric heart transplantation in HLA sensitized patients: evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation 2007; 116 (1 Suppl): I-172I-178.
29.Rossano JW, Morales DLS, Zafar F, et al. Impact of human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network of Organ Sharing Database. J Thorac Cardiovasc Surg 2010; 140: 694699.
30.Reed EF, Demetris AJ, Hammond E, et al. Acute antibody mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153159.
31.Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 5869.
32.Smith RN, Brousaides N, Grazette L, et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 2005; 24: 12021210.
33.Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005; 5: 27782785.
34.Di Filippo S, Gimita A, Webber SA, et al. Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome. Hum Immunol 2005; 66: 513518.
35.Jacobs JP, Asante-Korang A, O'Brien SM, et al. Lessons learned from 119 consecutive cardiac transplants for pediatric and congenital heart disease. Ann Thorac Surg 2011; 91: 12481255; PMID:21440154, April, 2011.
36.Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with Rituximab in cardiac transplantation. J Heart Lung Transplant 2005; 24: 13371342.
37.Girnita AL, Webber SA, Zeevi A. Anti-HLA antibodies in pediatric solid organ transplantation. Pediatr Transplant 2006; 10: 146153.
38.Taylor DO, Yowell RL, Kfoury AG, Hammond EH, Renlund DG. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000; 19: 518521.
39.Soleimani B, Lechler RI, Hornick PI, George AJ. Role of alloantibodies in the pathogenesis of graft arteriosclerosis in cardiac transplantation. Am J Transplant 2006; 6: 17811785.
40.Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 4853.
41.Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110: 26942700.
42.Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847858.
43.Costanzo MR, Dipchand A, Starling R, et al. The ISHLT Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914956.
44.Kobashigawa J, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009; 28: 213225.
45.Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80: 10191025.
46.Xydas S, Yang JK, Burke EM, et al. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 12891296.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Cardiology in the Young
  • ISSN: 1047-9511
  • EISSN: 1467-1107
  • URL: /core/journals/cardiology-in-the-young
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 6
Total number of PDF views: 89 *
Loading metrics...

Abstract views

Total abstract views: 345 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 19th October 2017. This data will be updated every 24 hours.